Robert Carlson, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111


Attending Physician

Breast Cancer TRDG Member


National Comprehensive Cancer Network®

Robert W. Carlson, MD, is Chief Executive Officer (CEO) of the National Comprehensive Cancer Network® (NCCN®). More at

Education and Training

Educational Background

  • Fellow, Medical Oncology, Stanford University, Stanford, CA, 1981-1983 
  • Senior Assistant Resident, General Internal Medicine, Stanford University, Stanford, CA, 1980 - 1981
  • Junior Assistant Resident, General Internal Medicine, Barnes Hospital Group, St. Louis, MO, 1979-1980 
  • MD, Stanford University Medical School, Stanford, California, 1978 

Honors & Awards

  • Best Doctors in America® , 2019-2020, Medical Oncology and Hematology
  • National Comprehensive Cancer Network Achievement Award, March 2000
  • Selected by America’s Top Doctors, 2001 – 2012
  • Best Doctors in America®, Best Doctors Inc , 2014
  • Breast Health Global Initiative, Founding Collaborator Award, 2010
  • National Comprehensive Cancer Network, Roger J. Winn, M.D. Award, 2010
  • National Physician of the Year for Clinical Excellence, 2008, Castle-Connolly Medical LTD
  • National Comprehensive Cancer Network, Special recognition and Appointment to the NCCN Board of Producers, 2004
  • Selected by Best Doctors in America, 1994–2011;



Selected Publications

Carlson RW, Wada HG, Sussman HH: The plasma membrane of human placenta:isolation of microvillus membrane and characterization of protein and glycoprotein subunits. The Journal of Biological Chemistry 251:4139-4146, 1976.  PubMed

Carlson RW, Sikic BI, Turbow MM, Ballon SC: Combination cisplatin, vinblastine and bleomycin chemotherapy (PVB) for malignant germ cell tumors of the ovary. J Clin Oncol 1(10):645-651, 1983.   PubMed

Bischoff MB, Shortliffe EH, Scott AC, Carlson RW, Jacobs CD: Integration of a computer-based consultant into the clinical setting. Proceedings of the Seventh Annual Symposium on Computer Applications in Medical Care, IEEE Press, Baltimore, MD, pp 149-152, 1983. PubMed

Picozzi VJ, Sikic BI, Carlson RW, Koretz M, Ballon SC: Bleomycin, mitomycin C and cisplatin therapy for advanced squamous carcinoma of the uterine cervix. A phase II study of the Northern California Oncology Group. Cancer Treat Rep 69(7-8):903-905, 1985.  PubMed

Kent DL, Shortliffe EH, Carlson RW, Bischoff MB, Jacobs CD: Improvements in data collection through physician use of a computer-based chemotherapy treatment consultant. J Clin Oncol 3(10):1409-1417, 1985.  PubMed

Carlson RW, Billingham ME, Kohler M, Johnson FD, Doroshow JH, Torti FM: Esorubicin in refractory metastatic carcinoma of the breast: A Northern California Oncology Group study. Cancer Treat Rep 71(4):427-428, 1987. PubMed 

Hancock SL, Goffinet DR, Carlson RW, Mark JBD: Esophageal cancer: Modest benefits from combined modality therapy. Radiology 164:603-606, 1987. PubMed

Carlson RW, Williams RD, Billingham ME, Kohler M, Torti FM: Phase II trial of Esorubicin in the treatment of metastatic carcinoma of the kidney: A study of the Northern California Oncology Group. Cancer Treat Rep 71(7-8):767-768, July/August   1987. PubMed

Tan Yew-OO, Hendrickson C, McWhirter K, Kohler M, Hannigan JF, Carlson RW: A phase II evaluation of oral medroxyprogesterone acetate (MPA) in advanced breast cancer: A Northern California Oncology Group study. Cancer Treat Rep 71(10):969- 970, October 1987. PubMed

Hu E, Stockdale FE, Turner B, Carlson RW, Levine J, Kushlan P: Combined modality therapy of locally advanced breast cancer. Anticancer Research 733-736, 1987.  PubMed

Connect with Fox Chase